We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
- Authors
Chang, A E; Shiling, D J; Stillman, R C; Goldberg, N H; Seipp, C A; Barofsky, I; Simon, R M; Rosenberg, S A
- Abstract
Fifteen patients with osteogenic sarcoma receiving high-dose methotrexate chemotherapy were studied in a randomized, double-blind, placebo-controlled trial of oral and smoked delta-9-tetrahydrocannabinol (THC) as an antiemetic. Each patient served as his or her own control. Fourteen of 15 patients had a reduction in nausea and vomiting on THC as compared to placebo. Delta-9-tetrahydrocannabinol was significantly more effective than placebo in reducing the number of vomiting and retching episodes, degree of nausea, duration of nausea, and volume of emesis (P less than 0.001). There was a 72% incidence of nausea and vomiting on placebo. When plasma THC concentrations measured less than 5.0 ng/mL, 5.0 to 10.0 ng/mL, and greater than 10.0 ng/mL, the incidences of nausea and vomiting were 44%, 21%, and 6%, respectively. Delta-9-tetrahydrocannabinol appears to have significant antiemetic properties when compared with placebo in patients receiving high-dose methotrexate.
- Publication
Annals of internal medicine, 1979, Vol 91, Issue 6, p819
- ISSN
0003-4819
- Publication type
Journal Article
- DOI
10.7326/0003-4819-91-6-819